Biogen Inc (BIIB) Return on Investment ROI from the first quarter of 2026 to first quarter of 2025 and for the year 2026, average high and low, overall ranking from Mar 31 2026 to Mar 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Biogen Inc   (NASDAQ: BIIB)


Biogen Inc's ROI from its first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Biogen Inc's ROI in the first quarter of 2026?
Biogen Inc achieved a return on average invested assets (ROI) of 5.29 % in its first quarter of 2026, which is below Biogen Inc's average return on investment, which stands at 15.03%.

ROI has improved compared to 5.17% in the fourth quarter of 2025, due to net income growth.

Within the Healthcare sector 34 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the fourth quarter of 2025 from 232 to 398.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Investment Change TTM 13.03 % 8.23 % 3.19 % -0.35 % -0.05 %
Y / Y Net Income Change TTM -7.26 % -20.79 % 17.8 % 56.65 % 276.03 %
Investment (TTM) in Millions 26,484 26,257 25,918 25,147 22,736
Return On Investment (TTM) 5.29 % 5.17 % 6.68 % 6.56 % 6.44 %
BIIB's Overall Ranking # 398 # 232 # 985 # 997 # 1053
Seq. Investment Change TTM 3.75 % 3.88 % 3.25 % 1.58 % -0.66 %
Seq. Net Income Change TTM 6.11 % -19.62 % 5.1 % 3.46 % -9.37 %
Net Income (TTM) in Millions 1,372 1,293 1,609 1,531 1,479

BIIB Company Profile >> Back to BIIB Roi Comparisons >> See Annual BIIB Return On Investment



Return On Investment BIIB's Ranking
Within: No.
Industry # 1
Sector # 35
Overall # 398

Return On Investment Statistics
High Average Low
33.77 %
15.03 %
0.45 %
(June 30. 2016)   (June 30. 2006)







Financial Statements
Biogen Inc's I. Quarter Investments $ 26,484 Millions BIIB's Balance sheet
Biogen Inc's I. Quarter Income $ 320 Millions Quarterly BIIB's Income Statement
BIIB's Income by Division See BIIB's Income by Division


BIIB Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 26,090 22,521 23,411 21,272 19,643
Y / Y Investment Growth 15.85 % -3.8 % 10.05 % 8.29 % -5.85 %
Net Income in Millions 1,293 1,632 1,162 2,962 1,728
Y / Y Net Income Growth -20.79 % 40.53 % -60.78 % 71.43 % -57.45 %
Annual Return On Investment 4.96 % 7.25 % 4.96 % 13.92 % 8.8 %


Annual Roi Comment
In the fiscal year 2025 ROI decreased relative to the previous year to 4.96 %, due to deterioration of net income.

Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
BIIB's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for BIIB's Competitors
Subscribers only: Roi for Biogen Inc's Suppliers
Subscribers only: Return On Investment for BIIB's Customers

Other Ratios
BIIB's Roa BIIB's Inventory Turnover Ratio BIIB's Growth Rates BIIB's Dividend Statistics
BIIB's Profitability Ratios BIIB's Asset Turnover Ratio BIIB's Dividend Growth
BIIB's Roe BIIB's Valuation Ratios BIIB's Financial Strength Ratios BIIB's Dividend Payout Ratio



Companies with similar Return On Investment at Mar 31 2026, within Healthcare Sector ROI
Lantheus Holdings Inc   14.24 %
Lifevantage Corp  13.20 %
Harmony Biosciences Holdings inc   13.07 %
Sbc Medical Group Holdings Incorporated  13.05 %
Johnson and Johnson  13.01 %
Progyny Inc   12.72 %
Universal Health Services Inc   12.68 %
Insulet Corporation  12.55 %
Encompass Health Corporation  12.43 %
Globus Medical Inc   12.37 %
Regeneron Pharmaceuticals Inc   12.19 %
Medinotec Inc   12.13 %
Msa Safety Inc  12.11 %
Healthcare Services Group Inc   12.09 %
Amgen Inc   12.04 %
Alpha Pro Tech Ltd   11.97 %
Kiniksa Pharmaceuticals International Plc  11.92 %
Prestige Consumer Healthcare Inc   11.89 %
Mimedx Group Inc   11.75 %
Ufp Technologies Inc   11.69 %
Ligand Pharmaceuticals Incorporated  11.46 %
Cryoport inc   11.23 %
Solventum Corporation  11.19 %
Nature s Sunshine Products inc   11.05 %
Bristol myers Squibb Company  10.72 %
Lemaitre Vascular Inc   10.60 %
Dr Reddy s Laboratories Limited  10.30 %
Siga Technologies Inc  10.04 %
Align Technology inc   9.99 %
Boston Scientific Corporation  9.95 %

Date modified: 2026-09-26T07:00:31+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.